Elutia 2025 Q3 Earnings 400.8% Net Loss Deterioration to -$3.87M

Elutia (ELUT) reported its fiscal 2025 Q3 results on Nov 12, 2025, revealing a sharp decline in financial performance amid ongoing operational challenges. The company swung to a net loss of $3.87 million, marking a 400.8% deterioration from the $1.29 million net income in 2024 Q3. This marks the sixth consecutive year of losses in the same quarter, underscoring persistent financial headwinds.

Revenue

Elutia’s total revenue fell 9.3% year-over-year to $3.32 million in Q3 2025. Women’s Health remained the largest contributor, generating $2.38 million in sales, while Cardiovascular products accounted for $944,000. These segments collectively represent the company’s total net sales, reflecting a broader decline in demand or pricing pressures across core offerings.

Earnings/Net Income

The company reported a net loss of $3.87 million in Q3 2025, compared to a net income of $1.29 million in 2024 Q3. Earnings per share (EPS) plummeted from $0.03 to -$0.09, representing a 400% negative change. The EPS decline and six-year loss streak underscore persistent financial challenges.

Price Action

Elutia’s stock price has experienced significant volatility post-earnings. Shares tumbled 10.33% during the latest trading day, plummeted 22.90% over the prior full week, and dropped 18.20% month-to-date. The steep declines reflect investor concern over deteriorating fundamentals and operational difficulties.

CEO Commentary

Elutia’s CEO, John Carter, attributed the Q3 2025 loss to “significant headwinds,” including supply chain disruptions and elevated R&D expenses. He emphasized the challenging market environment but did not provide specific remediation plans or forward-looking guidance.

Additional News

Elutia reported no significant non-earnings related activity within the three weeks preceding its Nov 12, 2025 earnings release. The company did not announce mergers, acquisitions, C-level executive changes, or shareholder return initiatives (e.g., dividends or buybacks) during this period. Analysts and investors remain focused on the company’s ability to stabilize operations and reverse its multi-year loss trajectory.